Haisco Pharmaceutical Group revenue and financials
¥62.18Change from previous close: +0.40%Absolute change: +¥0.25
In the fiscal year ended December 2025, Haisco Pharmaceutical Group reported revenue of ¥4.39B (+17.91% year over year). Net income was ¥259.58M, a net margin of 5.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +17.91%
- 2025 vs 2024
- Net income growth
- −34.36%
- 2025 vs 2024
- Net margin
- 5.9%
- 2024: 10.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 7,011 | 6,798 | 6,653 | 6,048 | — |
| Current assets | 2,834 | 2,730 | 2,641 | 2,054 | — |
| Cash and equivalents | 1,386 | 1,056 | 1,169 | 775 | — |
| Inventory | 307 | 272 | 281 | 346 | — |
| Net property, plant and equipment | 853 | 917 | 996 | 1,074 | — |
| Other intangible assets | 2,469 | 2,380 | 2,175 | 1,940 | — |
| Long-term investments | 139 | 105 | 132 | 185 | — |
| Current liabilities | 1,567 | 1,568 | 1,504 | 1,489 | — |
| Accounts payable | 166 | 196 | 209 | 242 | — |
| Long-term debt | 1,002 | 925 | 855 | 1,311 | — |
| Total debt | 1,980 | 1,910 | 1,807 | 2,103 | — |
| Total liabilities | 2,723 | 2,596 | 2,482 | 2,914 | — |
| Total equity (incl. minority) | 4,288 | 4,202 | 4,171 | 3,133 | — |
| Retained earnings | 1,691 | 1,757 | 1,792 | 1,441 | — |
| Minority interest | -2.0 | -11.1 | -9.4 | 97.7 | — |